BioNumerik Reports Preclinical Antitumor Data On Two Novel Supercomputer Engineered Anticancer Agents At 89th Annual AACR ...(

HOME >> MEDICINE >> NEWS

BioNumerik Reports Preclinical Antitumor Data On Two Novel Supercomputer Engineered Anticancer Agents At 89th Annual AACR Conference

- Novel class of highly lipophilic camptothecins, known as Karenitecins, demonstrates potent oral antitumor activity, acceptable safety and appear to be insensitive to common tumor-associated drug resistance mechanisms

- BioNumerik's novel chemoprotecting agent BNP7787 appears to completely protect against major toxicities associated with widely used platinum anticancer drugs such as cisplatinum

New Orleans, LA - March 30, 1998 -- BioNumerik Pharmaceuticals, Inc. this week presented new research results on two novel supercomputer-engineered small molecule agents designed to help address significant existing problems in current cancer therapy. These results continue to strengthen the correlation between actual experimental observations and the computational simulations provided by BioNumerik's innovative supercomputer simulations and mechanism based approach to new pharmaceutical discovery and development.

Regarding BioNumerik's BNP7787 and Karenitecins, Martin D. Abeloff, M.D., Director of the Johns Hopkins Oncology Center, stated, "These drugs have the potential to make a significant impact on current cancer therapy. The data reported by BioNumerik is particularly meaningful because the discovery and design of both of these agents was supported by BioNumerik's mechanism based computational studies and supercomputer simulations."

Frederick H. Hausheer, M.D., BioNumerik's Chairman and Chief Executive Officer, presented these findings at the 89th Annual Meeting of the American Association for Cancer Research held March 28 - April 1, 1998.

In a presentation titled "Karenitecins: A Novel Class of Orally Active Highly Lipophilic Topoisomerase I Inhibitors", the results presented by BioNumerik of studies conducted in BALB/c mice indicate that orally administered Karenitecin had excellent antitumor activity against solid tumors (prostate, colon, breast, lung) and had superior antitumor potency compared to existing camptothecin deriva
'"/>

Contact: Neil Cohen
neil@noonanrusso.com
212-696-4455 x. 205
Noonan/Russo Communications
30-Mar-1998

Page: 1 2 3 4 5
Related medicine news :

1. BioNumerik Reports Data On Two Novel Supercomputer Engineered Anticancer Agents At 90th Annual Meeting Of The AACR
2. BioNumerik Reports The Supercomputer Supported Discovery Of New, Non-Toxic Chemotherapy Protecting Agent
3. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
4. Melanoma Patients Sentinel Lymph Nodes (SLNS) Play A Strong Role In Disease Prognosis, UCSF Study Reports
5. Irritable Bowel Syndrome The Focus Of Three UNC-CH Reports At Digestive Diseases Conference
6. UCSF-Harvard Team Reports Encouraging Results In Drug Study Of Mice With Cancer
7. Bone Marrow With Heart And Lung Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
8. Bone Marrow With Organ Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
9. Changes In Levels Of LDLc From Pre- To Post-Menopausal Years Not Valuable Indicator Of Heart Disease, Reports University Of Pittsburgh Researcher
10. Medicare Policy Contradicts Preferred Treatment For Precancerous Skin Conditions, Westwood Squibb Center For Dermatology Research Reports
11. International Study Finds Statins Raise Good Cholesterol, Wake Forest Physician Reports

Post Your Comments: